Prostate-specific antigen testing accuracy in community practice

BMC Family Practice

Volumn 3, Issue , 2002, Pages 1-8

  Hoffman, Richard M ^a,b   Gilliland, Frank D ^c   Adams Cameron, Meg ^b   Hunt, William C ^b   Key, Charles R ^b  

^a NEW MEXICO VA HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Likelihood functions; Prostate specific antigen; Prostatic neoplasms; ROC curve; Sensitivity and specificity

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; CANCER SCREENING; CLINICAL TRIAL; COMMUNITY CARE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE BIOPSY; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; BIOPSY; CHEMISTRY; EVALUATION; MIDDLE AGED; PATHOLOGY; PROSTATE; PROSTATE TUMOR; ROC CURVE; STATISTICAL MODEL; UNITED STATES;

ADULT; AGE FACTORS; AGED; BIOPSY; HUMANS; LIKELIHOOD FUNCTIONS; MALE; MIDDLE AGED; NEW MEXICO; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 3342974457     PISSN: 14712296     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2296-3-19     Document Type: Article

References (39)

1. Jemal A, Thomas A, Murray T, Thun M: Cancer statistics, 2002. CA Cancer J Clin 2002, 52:23-47
2. Pienta KJ, Esper PS: Risk factors for prostate cancer. Ann Intern Med 1993, 118:793-803
3. Catalona WJ: Management of cancer of the prostate. New Engl J Med 1994, 331:996-1004
4. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB: Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994, 151:1283-1290
5. American Urological Association: Prostate-specific antigen (PSA) best practice policy. Oncology 2000, 14:267-280
6. Smith RA, Cokkinades V, von Eschenbach AC, Levin B, Cohen C, Runowicz CD, Sener S, Saslow D, Eyre HJ: American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin 2002, 52:8-22
7. United States Preventive Services Task Force: Guide to clinical preventive services. 2nd ed. Baltimore: Williams & Wilkins 1996
8. American College of Physicians: Screening for prostate cancer. Ann Intern Med 1997, 126:480-484
9. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. New Engl J Med 1991, 324:1156-1161
10. Brawer M, Chetner M, Beatie J, Buchner D, Vessela R, Lange P: Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992, 147:841-845
11. Babaian RJ, Mettlin C, Kane R, Murphy GP, Lee F, Drago JR, Chesley A: The relationship of prostate-specific antigen to digital rectal examination and transrectal ultrasonography. Cancer 1992, 69:1195-1200
12. Becker TM, Wiggins CL, Elliott RS, Key CR, Samet JM: Racial and ethnic patterns of mortality in New Mexico. Albuquerque, New Mexico: University of New Mexico Press 1993
13. StatSoft™: STATISTICA for the Macintosh. Tulsa, OK: StatSoft, Inc 1994
14. Hanley JA, McNeil BJ: The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982, 143:29-36
15. Sackett DL, Haynes RB, Guyatt GH, Tugwell P: Clinical Epidemiology. A basic science for clinical medicine. 2nd ed. Boston: Little, Brown & Company 1991
16. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, Lieber MM: Serum prostate-specific antigen in a community-based population of health men. Establishment of age-specific reference ranges. JAMA 1993, 270:860-864
17. Peirce JC, Cornell RG: Integrating stratum-specific likelihood ratios with the analysis of ROC curves. Med Decis Making 1993, 13:141-151
18. Jaeschke R, Guyatt GH, Sackett DL: Users' guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? JAMA 1994, 271:703-707
19. Brawer MK, Cheli CD, Neaman IE, Goldblatt J, Smith C, Schwartz MK, Bruzek DJ, Morris DL, Sokoll LJ, Chan DW, Yeung KK, Partin AW, Allard WJ: Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol 2000, 163:1476-1480
20. Catalona WJ, Richie JP, DeKernion JB, Ahmann FR, Ratliff TL, Dalkin BL, Kavoussi LR, MacFarlane MT, Southwick PC: Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. J Urology 1994, 152:2031-2036
21. Bangma CH, Kranse R, Blijenberg BG, Schröder FH: Free and total prostate-specific antigen in a screened population. Br J Urol 1997, 79:756-762
22. Ohori J, Dunn JK, Scardino PT: Is prostate-specific antigen density more useful than prostate-specific antigen levels in the diagnosis of prostate cancer? Urology 1995, 46:666-671
23. Labrie F, Dupont A, Suburu R, Cusan L, Tremblay M, Gomez J-L, Emond J: Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol 1992, 147:846-852
24. Gann PH, Hennekens CH, Stampfer MJ: A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995, 273:289-294
25. Gustafsson O, Norming U, Almgård L-E, Fredriksson A, Gustavsson G, Harvig B, Nyman CR: Diagnostic methods in the detection of prostate cancer: a study a randomly selected population of 2,400 men. J Urol 1992, 148:1827-1831
26. Jacobsen SJ, Bergstralh EJ, Guess HA, Katusic SK, Klee GG, Oesterling JE, Lieber MM: Predictive properties of serum prostate-specific antigen testing in a community-based setting. Arch Intern Med 1996, 156:2462-2468
27. Catalona WJ, Smith DS, Ratliff TL, Basler JW: Detection of organ-confined prostate cancer is increasing through prostate-specific antigen-based screening. JAMA 1993, 270:948-954
28. Richie JP, Catalona WJ, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, DeKernion JB: Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urology 1993, 42:365-374
29. Vallancien G, Prapotnich D, Veillon B, Brisset JM, Andre-Bougaran J: Systematic prostatic biopsies in 100 men with no suspicion of cancer on digital rectal examination. J Urol 1991, 146:1308-1312
30. Arcangeli CG, Smith DS, Ratliff TL, Catalona WJ: Stability of serum total and free prostate specific antigen under varying storage intervals and temperatures. J Urol 1997, 158:2182-2187
31. Woodrum D, French C, Shamel LB: Stability of free prostate-specific antigen in serum samples under a variety of sample collection and sample storage conditions. Urology 1996, 48:33-39
32. Morgan TO, Jacobsen SJ, McCarthy WF, Jacobsen DJ, McLeod DG, Moul JW: Age-specific reference ranges for serum prostate-specific antigen in black men. New Engl J Med 1996, 335:304-310
33. Moul JW, Sesterhenn IA, Connelly RR, Douglas T, Srivastava S, Mostofi FK, McLeod DG: Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. JAMA 1995, 274:1277-1281
34. Smith DS, Bullock AD, Catalona WJ: Racial differences in operating characteristics of prostate cancer screening tests. J Urol 1997, 158:1861-1865
35. Abdalla I, Ray P, Vaida F, Vijayakumar S: Racial differences in prostate-specific antigen levels and prostate-specific antigen densities in patients with prostate cancer. Am J Clin Oncol 1999, 22:537-541
36. Abdalla I, Ray P, Ray V, Vaida F, Vijayakumar S: Comparison of serum prostate-specific antigen levels and PSA density in African-American, white, and Hispanic men without prostate cancer. Urology 1998, 51:300-305
37. Catalona WJ, Smith DS, Ornstein DK: Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997, 277:1452-1455
38. Schröder FH, van der Cruisjen-Koeter I, de Koning HJ, Vis AN, Hoedemaker RF, Kranse R: Prostate cancer detection at low prostate specific antigen. J Urol 2000, 163:806-812
39. Lodding P, Aus G, Bergdahl S, Frosing R, Lilja H, Pihl CG, Hugosson J: Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng./ml. Prostate specific antigen. J Urol 1998, 159:899-903